pharmaceutical manufacturing
in 2021, the revenue of pharmaceutical manufacturing segment by fosun pharma amounted to rmb 28.904 billion, representing a yoy increase of 32.10%. the revenue from new products and sub-new products accounted for more than 25% of the revenue in pharmaceutical manufacturing segment, and the revenue structure continued to be optimized.
in 2021, fosun pharma promoted the strategic integration of the manufacturing end by sorting out the internal advantageous capacity of the pharmaceutical manufacturing segment, strengthening supply chain management, and accelerating the construction of competitive production bases. at the beginning of 2022, the pharmaceutical manufacturing segment was upgraded and divided into the innovative medicines division, established medicines manufacturing & supply division and vaccines division, and the business boundary was sorted out for each division to accelerate the focus on sublines.
fosun pharma has many advantageous products in oncology and immunomodulation, anti-infection, metabolism and digestive system, central nervous system, cardiovascular system and other fields.
-
-
-
major products of oncology and immunomodulation
in 2021, the revenue generated from oncology and immunomodulatory core drugs showed a yoy increase of 145.23%, mainly due to the increase of han li kang (rituximab injection), han qu you (trastuzumab injection, zercepac® in the eu) and su ke xin(avatrombopag maleate tablets).
in 2021, revenue from han li kang (rituximab injection), reached rmb1,690 million, representing a yoy increase of 125.33%; han qu you (trastuzumab injection, zercepac® in the eu) and su ke xin (avatrombopag maleate tablets), which were launched in the second half of 2020 achieved revenue of rmb 930 million and rmb 426 million, respectively, in 2021.
-
-
-
-
major products of metabolism and digestive system
major products of metabolism and digestive system include atomolan tablets (glutathione tablets), atomolan injection (reduced glutathione for injection), animal insulin and its preparations, yi bao (recombinant human erythropoietin for injection (cho cells)), you li tong (febuxostat tablets), potassium chloride granules, ke yi (compound aloe capsules), li qing (alfacalcidol tablets), fan ke jia (thioctic acid injection) and wan su ping (glimepiride tablets).
in 2021, yi bao (recombinant human erythropoietin for injection) for the treatment chemotherapy-induced anemia in patients with non-myeloid malignancies was approved for launch in chinese mainland. atomolan tablets (glutathione tablets) had a sales revenue of more than rmb 500 million in 2021.
-
-
-
-
major products of anti-infection
in 2021, the revenue of anti-infection major products increased by 119.54% yoy, mainly due to the revenue contribution of comirnaty (mrna covid-19 vaccine, also known as bnt162b2) and the increase in sales revenue of micafungin and mei shi lin (cefminox sodium for injection) during the reporting period. comirnaty® (mrna covid-19 vaccine) jointly developed by fosun pharma and biontech, was included in the government vaccination programs in hong kong sar and macau sar in march 2021 and supplied to the taiwan region in september 2021. by the end of february 2022, over 20 million doses of bnt162b2 have been administrated in hong kong sar, macau sar, and taiwan region, helping to establish the local covid-19 immune barrier.
by the end of 2021, artesun® (artesunate for injection), self-developed and manufactured by fosun pharma, has been used to treat over 48 million severe malaria patients worldwide by the end of 2021, which turned to be a symbol of china's self-developed innovative medicines to the world.
-
-
-
-
major products of central nervous system
major products of the central nervous system include qi wei (quetiapine fumarate tablets), chang tuo ning (penehyclidine hydrochloride injection), ao de jin (deproteinized calf blood injection) and qi cheng (escitalopram tablets)
-
-
-
-
major products of cardiovascular system
major products of cardiovascular system comprise heparin series preparations, bang tan (telmisartan tablets), bang zhi (pitavastatin calcium tablets), ke yuan (calcium dobesilate capsules), xin xian an (meglumine adenosine cyclophosphate for injection), you di er (alprostadil dried emulsion for injection), ya ni an/shi li da (amlodipine besylate tablets) and indapamide tablets
-
-
-
-
major products of apis and intermediates
in 2021, the revenue from core products of apis and intermediates increased by 9.56% yoy, mainly due to the increase in the sales revenue of the amino acid series products. major products of apis and intermediates include amino acid series, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride.
-